Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. - sprookjes - yvandenbroek - TriplyDB

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

http://www.wikidata.org/entity/Q33346277

about

Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head H5N1 vaccines in humans Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques Evolution of H3N2 influenza virus in a guinea pig model GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses New vaccines against influenza virus.The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.Prospects for developing an effective particle-mediated DNA vaccine against influenza.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Advances in novel influenza vaccines: a patent review.An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device.A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin.Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans.New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.Targets for the induction of protective immunity against influenza a viruses.Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin.Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device.Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development.DNA vaccines: ready for prime time?Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques.New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo

P2860

Q24642027-367473E1-865A-4EE2-9CDC-E14581135A78 Q26783897-DEEFAEB9-608F-4A1F-B7F9-E6B05A4A6434 Q27000896-8C1AB88D-7741-451C-8474-8DA19F921401 Q27013568-8A2D0EA1-2B16-4BBC-A2CE-407A3A0E4A3E Q27348520-B2CF23BB-9F85-4D98-9644-6B367E18A20F Q28236770-B0DAC439-3BF0-4356-88AF-DF4063F97B4F Q28728563-22A0ED68-69F3-4F76-BE9A-951D8B85908E Q28742283-52329291-1FC1-4914-A15F-FE4AE1E82D28 Q28751705-377B20CB-DC6E-42CE-BF19-C27AE1834857 Q30227194-8CEAAD78-D941-4A30-98AA-0F33CCE16C14 Q30228657-CC307647-2DED-4FE2-90D4-AE225015BA6F Q30357932-713EE5ED-B55A-425A-93B2-74A84791F5A4 Q30372479-F56EBF9B-1906-42E8-92D6-56C435A38E59 Q30375991-36181DC7-154E-49CB-8985-805F77BC2532 Q30380300-60B94E2E-5CC5-40C8-A934-FB8864F4F39F Q30382097-B99FFEEF-1A1D-4F3B-B7F6-4FD0E0CF8796 Q30388514-DB8674E2-BA56-4C77-B831-B97FAFBEF029 Q30391315-A360F8EF-8053-4AC0-9EC9-DD489DDA85FD Q30392828-CDA579CB-F56C-402E-B5DE-EDBBB707B4F1 Q30395101-39D55D60-3860-4DED-96D8-4FC963D7782D Q30398956-EF89BD2D-446C-4602-907A-74646DB548E2 Q30399675-0D34F777-F12C-4A50-AFF4-143566F4FDEA Q30401519-496B9CA4-475F-4666-B165-7FEAEAE0276B Q30403507-DD6491BD-3468-4CA7-9C3F-6ACFF97870ED Q30407424-96BA1DA1-035D-4026-9353-690AFF453BE3 Q30408100-198F8BEC-C757-48D0-9B16-0D2131C5AE33 Q30408295-5D265963-82A3-44BA-A92F-DE716321036B Q30427591-8040B20A-593A-4AA5-A714-54842F074C66 Q30913948-BB808DA2-8BFE-4EFD-B761-2FD8ABDA6CF9 Q33586294-83DD30D7-0E7E-40C0-AEA7-FDCC96B78F09 Q33690988-DB23F742-B29C-480A-91E6-DA771C0788A3 Q33713435-AF43EABA-C89B-4858-A631-17DE608F1F00 Q33723334-B1C0328C-0809-47BE-8488-F4AB8F66E62C Q33829920-B4653158-A3AD-4CEE-81FD-7E8D414E15A2 Q33987553-59464E5E-FF8E-405C-8C49-8E7BC1E85BC4 Q34472018-E8ECC5FB-8653-432A-91F6-7A58EE10E8A9 Q34824179-A6670023-9421-42CF-A09E-68149D5A77EE Q34985353-A9D6EBAB-6996-4096-AA0E-EEF7D003A8AC Q35078213-7AB5043B-29C5-4CFB-8AE4-1B6BD10E1BB5 Q35082880-819B86A2-49E4-438F-BF23-FCA4AC11D20A

P2860

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

http://www.wikidata.org/entity/Q33346277

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Heterosubtypic protection agai ...... thetic consensus DNA antigens.

@ast

Heterosubtypic protection agai ...... thetic consensus DNA antigens.

@en

type

label

Heterosubtypic protection agai ...... thetic consensus DNA antigens.

@ast

Heterosubtypic protection agai ...... thetic consensus DNA antigens.

@en

prefLabel

Heterosubtypic protection agai ...... thetic consensus DNA antigens.

@ast

Heterosubtypic protection agai ...... thetic consensus DNA antigens.

@en

P1433

Q33346277-A2F00A9C-ADE6-4A4A-B37F-70E1897F79A4

P1476

Q33346277-B12365BC-8220-4866-BE9D-503C464B3DD8

P2093

Q33346277-227AFAF4-100B-48BB-B239-778B675A236D

Q33346277-6462A6B4-70D3-4A54-9477-2A26E96CC68B

Q33346277-A95DB051-3771-4EF9-B3FC-77D1AE74A8EC

Q33346277-B5DF9BCA-0D42-4CD2-AEBB-9C7174734B2F

Q33346277-B97D77DC-8A69-4821-8A11-B6D1D1B4AFAC

Q33346277-C96D29BB-247B-40DA-B150-9F89F4262CD8

Q33346277-EDB77FAA-FD91-48E4-8FEA-5A1159BF9E5E

Q33346277-FA93A813-6701-4E68-BC6E-F4926F393EA1

P2860

Q33346277-1B63D46E-CDEA-4E4C-B55B-222F44BA88BF

Q33346277-202342F5-3967-4EA2-B4D9-8ED516C6AC2C

Q33346277-330D7E3D-154F-4F8F-B35F-9BFCA29CDFB9

Q33346277-3454B00B-F949-4A48-B58A-74F8EF3A54F3

Q33346277-43CEE23C-4FF9-4BF0-B2BE-9A4AE301626B

Q33346277-47F4715C-1112-4A27-8455-0E757F71E1F1

Q33346277-506425B5-F0E5-4DE1-BABE-AA62572682EB

Q33346277-533CB43D-D4AD-4C33-90FD-630D215DD715

Q33346277-6FBC7402-C44E-4D70-9426-9F68A0653828

Q33346277-7BF9A4F8-B1AB-499E-A8F8-0C77D8FFD322

P304

Q33346277-26C5DB93-FE37-458C-BF27-2F1887499FBA

P31

Q33346277-240E14CF-53ED-450D-9697-47558B109EF7

P356

Q33346277-979C57ED-E962-491C-B229-B552238B3534

P407

Q33346277-194F57C9-8ECB-4CE1-B321-77F136A2204B

P433

Q33346277-4A33064F-E238-4EEF-A633-DFB93CA1990D

P478

Q33346277-BCB605A9-7764-499C-9AEA-D18E875EB817

P50

Q33346277-4D3D4245-0634-4FC6-99D7-5CE944FB0E7C

Q33346277-F20E45E1-6954-4120-A90E-F2B9077A0B05

P577

Q33346277-AF17D916-FDC5-451B-953D-15509A3D34D0

P5875

Q33346277-888C320A-5994-4A4F-8DF3-031D0553FD2D

P698

Q33346277-CADD58B6-4478-41FF-947C-5606AA10404E

P921

Q33346277-EB42024D-DDAD-4B94-9A4F-1F2C0E5780E1

P932

Q33346277-717DD043-A141-4D83-B52C-4F17FAA0F4B7

P356

JOURNAL.PONE.0002517

P1433

P1476

Heterosubtypic protection agai ...... thetic consensus DNA antigens.

@en

P2093

Amir S Khan

http://www.w3.org/2001/XMLSchema#string

David B Weiner

http://www.w3.org/2001/XMLSchema#string

Dominick J Laddy

http://www.w3.org/2001/XMLSchema#string

Jack Greenhouse

http://www.w3.org/2001/XMLSchema#string

Jian Yan

http://www.w3.org/2001/XMLSchema#string

Michele Kutzler

http://www.w3.org/2001/XMLSchema#string

Niranjan Y Sardesai

http://www.w3.org/2001/XMLSchema#string

Ruxandra Draghia-Akli

http://www.w3.org/2001/XMLSchema#string

P2860

Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

From plasmids to protection: a review of DNA vaccines against infectious diseases

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

Cell-mediated protection in influenza infection.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein

P304

e2517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0002517

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Gary P. Kobinger

P577

2008-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5279927

http://www.w3.org/2001/XMLSchema#string

P698

18575608

http://www.w3.org/2001/XMLSchema#string

P921

electroporation

P932

2429965

http://www.w3.org/2001/XMLSchema#string